AI drug discovery screening for COVID-19 reveals zafirlukast as a repurposing candidate

World Health Organization, 2020, Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update Wang, 2020, A novel coronavirus outbreak of global health concern, Lancet, 395, 470, 10.1016/S0140-6736(20)30185-9 Wrapp, 2020, Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies, Cell, 181, 1004, 10.1016/j.cell.2020.04.031 Vamathevan, 2019, Applications of machine learning in drug discovery and development, Nat Rev Drug Discov, 18, 463, 10.1038/s41573-019-0024-5 Wong, 2019, Estimation of clinical trial success rates and related parameters, Biostatistics, 20, 273, 10.1093/biostatistics/kxx069 Vernon, 2010, Drug development costs when financial risk is measured using the Fama–french three-factor model, Health Econ, 19, 1002, 10.1002/hec.1538 Zumla, 2020, Reducing mortality from 2019-ncov: host-directed therapies should be an option, Lancet, 395, e35, 10.1016/S0140-6736(20)30305-6 Zhou, 2020, Artificial intelligence in COVID-19 drug repurposing, Lancet Digit Health, 2, e667, 10.1016/S2589-7500(20)30192-8 Ke, 2020, Artificial intelligence approach fighting COVID-19 with repurposing drugs, Biom J, 43, 355 Gao, 2020, Repositioning of 8565 existing drugs for COVID-19, J Phys Chem Lett, 11, 5373, 10.1021/acs.jpclett.0c01579 Beck, 2020, Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model, Comput Struct Biotechnol J, 18, 784, 10.1016/j.csbj.2020.03.025 Levin, 2020, Artificial intelligence, drug repurposing and peer review, Nat Biotechnol, 38, 1127, 10.1038/s41587-020-0686-x Zhang, 2020, Deep learning based drug screening for novel coronavirus 2019-nCov, Interdiscip Sci, 12, 368, 10.1007/s12539-020-00376-6 Mohanty, 2020, Application of Artificial Intelligence in COVID-19 drug repurposing, Diabetes Metab Syndr, 14, 1027, 10.1016/j.dsx.2020.06.068 Kandeel, 2020, Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease, Life Sci, 251, 10.1016/j.lfs.2020.117627 Parvathaneni, 2020, Utilizing drug repurposing against COVID-19–efficacy, limitations, and challenges, Life Sci, 259, 10.1016/j.lfs.2020.118275 Hoffmann, 2020, SARS-CoV-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor, Cell, 181, 271, 10.1016/j.cell.2020.02.052 Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5 Wu, 2020, A new coronavirus associated with human respiratory disease in China, Nature, 579, 265, 10.1038/s41586-020-2008-3 Xu, 2020, Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission, Sci China Life Sci, 63, 457, 10.1007/s11427-020-1637-5 Rossi, 2020, Differences and similarities between sars-cov and SARS-CoV-2: spike receptor-binding domain recognition and host cell infection with support of cellular serine proteases, Infection, 1 Kowalewski, 2020, Predicting novel drugs for SARS-CoV-2 using machine learning from a> 10 million chemical space, Heliyon, 6, 10.1016/j.heliyon.2020.e04639 Sanghai, 2020, Taming the cytokine storm: repurposing montelukast for the attenuation and prophylaxis of severe COVID-19 symptoms, Drug Discov Today, 25, 2076, 10.1016/j.drudis.2020.09.013 Almerie, 2020, The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast, Med Hypotheses, 143, 10.1016/j.mehy.2020.109883 National Center for Biotechnology Information, 2020 Jin, 2020, Structure of m pro from SARS-CoV-2 and discovery of its inhibitors, Nature, 1 Mahdi, 2020, Analysis of the efficacy of hiv protease inhibitors against SARS-CoV-2 s main protease, Virol J, 17, 1, 10.1186/s12985-020-01457-0 Tripathi, 2020, Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2, Int J Biol Macromol, 164, 2622, 10.1016/j.ijbiomac.2020.08.166 Abian, 2020, Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening, Int J Biol Macromol, 164, 1693, 10.1016/j.ijbiomac.2020.07.235 Sterling, 2015, Zinc 15–ligand discovery for everyone, J Chem Inf Model, 55, 2324, 10.1021/acs.jcim.5b00559 Kinch, 2014, An overview of FDA-approved new molecular entities: 1827–2013, Drug Discov Today, 19, 1033, 10.1016/j.drudis.2014.03.018 Yang, 2019, Analyzing learned molecular representations for property prediction, J Chem Inf Model, 59, 3370, 10.1021/acs.jcim.9b00237 Landrum Chen, 2016, Xgboost: A scalable tree boosting system, 785 Lematre, 2017, Imbalanced-learn: a python toolbox to tackle the curse of imbalanced datasets in machine learning, J Mach Learn Res, 18, 559 Wu, 2018, Moleculenet: a benchmark for molecular machine learning, Chem Sci, 9, 513, 10.1039/C7SC02664A Maaten, 2008, Visualizing data using t-sne, J Mach Learn Res, 9, 2579 Funk, 2020, A novel strategy to mitigate the Hyperinflammatory response to COVID-19 by targeting leukotrienes, Front Pharmacol, 11, 1214, 10.3389/fphar.2020.01214 Twaites, 2007, Safety of zafirlukast, Drug Saf, 30, 419, 10.2165/00002018-200730050-00005 Miller, 2010, Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action, Biochem Pharmacol, 79, 1272, 10.1016/j.bcp.2009.12.021 Wu, 2020, Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharm Sin B, 10, 766, 10.1016/j.apsb.2020.02.008 Donkers, 2017, Reduced hepatitis b and d viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter ntcp, Sci Rep, 7, 1, 10.1038/s41598-017-15338-0 Martinez, 2018, Breathing new life into West Nile virus therapeutics; discovery and study of zafirlukast as an NS2B-NS3 protease inhibitor, Eur J Med Chem, 157, 1202, 10.1016/j.ejmech.2018.08.077 Seidah, 2006, Unexpected similarity between the cytosolic West Nile virus NS3 and the secretory furin-like serine proteinases, Biochem J, 393, 1, 10.1042/BJ20051787 Pantos, 2020, Use of triiodothyronine to treat critically ill COVID-19 patients: a new clinical trial, Crit Care, 24, 1, 10.1186/s13054-020-02934-2 Pantos, 2020, Triiodothyronine for the treatment of critically ill patients with COVID-19 infection: a structured summary of a study protocol for a randomised controlled trial, Trials, 21, 1, 10.1186/s13063-020-04474-0 Gomeni, 2020, Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS COV-2, J Pharmacokinet Pharmacodyn, 1 Dash, 2020, Sulfonamides: antiviral strategy for neglected tropical disease virus, Curr Organ Chem, 24, 1018, 10.2174/1385272824999200515094100 Supuran, 2004, Antiviral sulfonamide derivatives, Mini Rev Med Chem, 4, 189, 10.2174/1389557043487402 Poddighe, 2020, Clinical evidences on the antiviral properties of macrolide antibiotics in the COVID-19 era and beyond, Antivir Chem Chemother, 28, 10.1177/2040206620961712